viernes, 13 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Which Pharma Stock Stands Taller Right Now: LLY or PFE?

View original at finance.yahoo.com
Which Pharma Stock Stands Taller Right Now: LLY or PFE? Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. pharmaceutical leaders, each backed by diversified product portfolios and robust R&D engines…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • COVID revenues expected to be around $5 billion in 2026, $1.5 billion less than expected sales of about $6.5 billion in 2025

    80% confidence

  • Pfizer's 2026 EPS expected to decline 4.2% year-over-year

    80% confidence

  • Lilly's 2026 sales expected to increase 22.6% year-over-year

    80% confidence

  • Cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027

    80% confidence

  • Data readouts from three phase III studies on retatrutide for treating obesity expected in the second half of 2026

    80% confidence

  • Pfizer's 2026 sales expected to decline 2.1% year-over-year

    80% confidence

  • Mounjaro and Zepbound are expected to continue to see strong demand in 2026

    80% confidence

  • Lilly's 2026 EPS expected to increase 39.5% year-over-year

    80% confidence

  • Loss of exclusivity cliff expected to hurt sales by approximately $1.5 billion in 2026

    80% confidence

  • Lilly is a clear winner over Pfizer due to exceptional growth from Mounjaro and Zepbound, product and pipeline portfolio in high-growth therapeutic areas like obesity, robust growth prospects and bullish analyst sentiment

    80% confidence

  • Orforglipron has potential to be approved and launched in 2026

    80% confidence

  • Metsera candidates expected to generate billions of dollars in peak sales

    80% confidence

  • New and acquired products expected to deliver double-digit growth in 2026

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
Which Pharma Stock Stands Taller Right Now: LLY or PFE? — Source | Via News | es.VIA.NEWS